Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver v...
Principais autores: | Mensah, V, Gueye, A, Ndiaye, M, Edwards, N, Wright, D, Anagnostou, N, Syll, M, Ndaw, A, Abiola, A, Bliss, C, Gomis, J, Petersen, I, Ogwang, C, Dieye, T, Viebig, N, Lawrie, A, Roberts, R, Nicosia, A, Faye, B, Gaye, O, Leroy, O, Imoukhuede, E, Ewer, K, Bejon, P, Hill, A, Cisse, B, MVVC Group |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Public Library of Science
2016
|
Registros relacionados
-
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
por: Victorine A Mensah, et al.
Publicado em: (2016-01-01) -
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
por: Bliss, C, et al.
Publicado em: (2016) -
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, AB, et al.
Publicado em: (2018) -
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
por: Ogwang, C, et al.
Publicado em: (2013) -
A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
por: De Barra, E, et al.
Publicado em: (2014)